✦ LIBER ✦

Rationale, design, and baseline characteristics of a Program to Assess and Review Trending INformation and Evaluate CorRelation to Symptoms in Patients with Heart Failure (PARTNERS HF)

✍ Scribed by David J. Whellan; Christopher M. O'Connor; Kevin T. Ousdigian; Te-Hsin Lung

Book ID: 116191520
Publisher: Elsevier Science
Year: 2008
Tongue: English
Weight: 218 KB
Volume: 156
Category: Article
ISSN: 1097-6744
DOI: 10.1016/j.ahj.2008.06.036

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Combined Heart Failure Device Diagnostic

Combined Heart Failure Device Diagnostics Identify Patients at Higher Risk of Subsequent Heart Failure Hospitalizations: Results From PARTNERS HF (Program to Access and Review Trending Information and Evaluate Correlation to Symptoms in Patients With Heart Failure) Study

✍ David J. Whellan; Kevin T. Ousdigian; Sana M. Al-Khatib; Wenji Pu; Shantanu Sark 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 348 KB

Changes in Intrathoracic Fluid Index pre

Changes in Intrathoracic Fluid Index predict subsequent adverse events: Results of the Multi-site Program to Access and Review Trending INformation and Evaluate CoRrelation to Symptoms in Patients with Heart Failure (PARTNERS HF) Trial

✍ David J. Whellan; Sana M. Al-Khatib; Esteban Martin Kloosterman; Steven P. Kutal 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 86 KB

Organized program to initiate lifesaving

Organized program to initiate lifesaving treatment in hospitalized patients with heart failure (OPTIMIZE-HF): rationale and design

✍ Gregg C Fonarow; William T Abraham; Nancy M Albert; Wendy A Gattis; Mihai Gheorg 📂 Article 📅 2004 🏛 Elsevier Science 🌐 English ⚖ 276 KB

Organized program to initiate lifesaving

Organized program to initiate lifesaving treatment in hospitalized patients with heart failure (OPTIMIZE-HF): rationale and design

✍ Gregg C Fonarow; William T Abraham; Nancy M Albert; Wendy A Gattis; Mihai Gheorg 📂 Article 📅 2004 🏛 Elsevier Science 🌐 English ⚖ 276 KB

Heart failure (HF) affects >5 million patients in the United States, and its prevalence is increasing every year. Despite the compelling scientific evidence that angiotensin-converting enzyme inhibitors and β-blockers reduce hospitalizations and mortality rates in patients with HF, these lifesaving

A randomized controlled trial to evaluat

A randomized controlled trial to evaluate the safety and efficacy of cardiac contractility modulation in patients with systolic heart failure: Rationale, design, and baseline patient characteristics

✍ William T. Abraham; Daniel Burkhoff; Koonlawee Nademanee; Peter Carson; Robert B 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 615 KB

Rationale and Design of the IRON-HF Stud

Rationale and Design of the IRON-HF Study: A Randomized Trial to Assess the Effects of Iron Supplementation in Heart Failure Patients With Anemia

✍ Luís Beck-da-Silva; Luís Eduardo Rohde; Antônio Carlos Pereira-Barretto; Denílso 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 106 KB